JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning | BioPharma Dive
SAN FRANCISCO — For any hopes the dealmaking that started the J.P. Morgan Healthcare Conference would give the overall biotechnology sector a running start to 2025, Eli Lilly deflated them Tuesday. The company…
Read guide →